Lanean...
Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737
BACKGROUND: Despite the high complete response rates with fludarabine-based regimens, relapse is inevitable in chronic lymphocytic leukemia (CLL). Relapsed patients often acquire 17p deletions [del(17p)], which are closely associated with TP53 mutations. Wild-type p53 upregulates and activates BAX,...
Gorde:
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2011
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3579224/ https://ncbi.nlm.nih.gov/pubmed/21761401 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26360 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|